Dual Nucleoside Analogue Therapy for Feline Infectious Peritonitis: A Clinical Evidence Review for Veterinary Practitioners

A review of the pharmacological basis and published data supporting GS-441524 and EIDD-1931 combination treatment for Feline Infectious Peritonitis (FIP) in cats.

Dual Nucleoside Analogue Therapy for Feline Infectious Peritonitis: A Clinical Evidence Review for Veterinary Practitioners

Background

Feline Infectious Peritonitis (FIP), caused by virulent biotypes of feline coronavirus (FCoV), transitioned from a uniformly fatal disease to a treatable condition with the introduction of GS-441524 in 2019. Standard monotherapy (4-10 mg/kg, 84 days) achieves consistently high remission rates across effusive, non-effusive, ocular, and neurological presentations. However, monotherapy carries inherent limitations: resistance potential under prolonged selective pressure, suboptimal CNS penetration, and incomplete viral clearance in a patient subset.

CURE FIP™ Dual Antiviral Oral Capsules address these through orthogonal mechanism targeting, combining GS-441524 (chain terminator) and EIDD-1931 (lethal mutagen) in a single oral formulation.

Pharmacological Basis

GS-441524: Chain Termination

Adenosine nucleoside analogue. After intracellular phosphorylation to GS-443902, acts as RdRp substrate. 1'-cyano substitution causes steric clash, resulting in delayed chain termination and cessation of viral RNA synthesis (Murphy et al., Vet Microbiol, 2018). Non-cytotoxic at 100x effective dose in CRFK cells. Plasma half-life ~24h supports q24h dosing.

EIDD-1931: Lethal Mutagenesis

Active metabolite of molnupiravir (EIDD-2801). Mutagenic ribonucleoside incorporating into viral RNA without immediate chain termination. Induces C-to-U and G-to-A transition mutations across successive replication rounds until cumulative burden exceeds error threshold, causing viral population collapse through error catastrophe. Feline PK confirmed: Cmax ~1,551 ng/mL (~6 μM), detectable 12h post-dose (Pathogens, 2025).

Synergistic Rationale

Chain termination directly reduces viral RNA output. Lethal mutagenesis degrades fidelity of remaining copies. Combined: faster effective viral population reduction and substantially higher genetic barrier to resistance, requiring simultaneous escape mutations against orthogonal mechanisms.

Published Clinical Evidence

GS-441524 Monotherapy

Pedersen et al. (2019): UC Davis. 31 cats, naturally occurring Feline Infectious Peritonitis (FIP). GS-441524 2.0-4.0 mg/kg SC q24h, min. 12 weeks. 24/26 completers in sustained remission. Fever resolution 12-36h, effusion resolution 10-14d. JFMS, 21(4):271-281

Coggins et al. (2023): 307 cats, legally sourced RDV/GS-441524 (Australia, UK). 84.4% alive at longest follow-up (median 248d). Relapse 10.8% (33/307). JVIM

Krentz et al. (2024): Prospective RCT, LMU Munich. 40 cats effusive Feline Infectious Peritonitis (FIP), 15 mg/kg PO q24h, 42 vs 84d. 38/40 recovered. Significant viral RNA reduction. Pathogens

Delaplace et al. (2025): PRISMA systematic review. 11 studies, 650 cases. Overall success 84.6%. Higher with combination therapy. Effusive OR ~0.49 vs non-effusive. Neuro: GS+RDV 10/10, GS+GC376 7/8 survived. Pathogens

Molnupiravir/EIDD-1931

Kanai et al. (2023): 18 cats, MPV 10-20 mg/kg PO q12h, 84d. 14/14 completers in remission (139-206d follow-up). Transient ALT in 3 cats. JVIM

Kanai et al. (2024): 118 cats, 59 GS vs 59 MPV. Remission: GS 48/48, MPV 51/52. Mortality comparable (20.3% vs 13.6%, p=0.326). Front Vet Sci

Roy et al. (2022): Ohio State. 26 cats post-GS failure. 24/26 disease-free. AEs >23 mg/kg q12h only. Pathogens

Combination Therapy

Li et al. (2022): 46 cats, GS+GC376, 4 weeks. 45/46 (97.8%) survived. All 45 relapse-free at 10 months. Front Vet Sci

Clinical Guidance

Neurological Feline Infectious Peritonitis (FIP)

CSF penetration of GS-441524: 7-21% of plasma, with inter-individual variability. 2025 systematic review confirmed combination therapy significantly improves neurological outcomes. EIDD-1931 provides supplementary antiviral pressure compensating for limited CNS drug levels.

Resistance

GS-441524 resistance during 84-day monotherapy is documented. Dual mechanisms raise the genetic barrier substantially by requiring simultaneous escape from chain termination and lethal mutagenesis.

Relapse

~10-11% relapse rate in GS-441524 monotherapy studies. Dual therapy may reduce residual viral reservoirs more effectively. EIDD-1931 has proven efficacy as rescue agent for GS-refractory cases.

Monitoring

CBC (neutrophil counts), biochemistry (ALT), body weight, clinical signs at regular intervals. Liver support advisable. Post-treatment observation minimum 12 weeks for relapse monitoring.

Summary

GS-441524 + EIDD-1931 combination represents a pharmacologically rational evolution in Feline Infectious Peritonitis (FIP) management. Orthogonal mechanism targeting offers enhanced viral suppression, higher resistance barrier, and potentially improved outcomes in challenging presentations including neurological Feline Infectious Peritonitis (FIP). Individual and combination evidence provides a compelling rationale for dual nucleoside analogue therapy.

Clinical consultation: basmifipindia.com | WhatsApp support available.